Section Arrow
Quote
FTRE.NASDAQ
- Fortrea Holdings
Quotes are at least 15-min delayed:2026/02/23 19:04 EST
After Hours
Last
 10.1908
-0.6592 (-6.08%)
Bid
8.62
Ask
11.34
High 10.84 
Low 10.1908 
Volume 31.74K 
Regular Hours (Closed)
Last
 10.85
-0.15 (-1.36%)
Day High 
10.91 
Prev. Close
11 
1-M High
17.81 
Volume 
198.76K 
Bid
8.62
Ask
11.34
Day Low
10.32 
Open
10.91 
1-M Low
9.2 
Market Cap 
1.02B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 11.7 
20-SMA 14.08 
50-SMA 15.72 
52-W High 18.67 
52-W Low 3.97 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.21/1.37
Enterprise Value
2.13B
Balance Sheet
Book Value Per Share
6.29
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
2.70B
Operating Revenue Per Share
33.35
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.4042 -0.01635 -3.89%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.83 +0.01 +0.10%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.2816 +0.1116 +1.37%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.82 +0.02 +1.11%
KLTOKlotho Neurosciences Inc0.41+0.1573+62.25%-- 
After Hours 0.38 -0.03 -7.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.